Pricing Log in Create free account

Brainstorm Cell Therapeutics Inc. (BCLI) vs IMMURON (IMRN)

Brainstorm Cell Therapeutics Inc. and IMMURON are both Biotechnology companies. Brainstorm Cell Therapeutics Inc. and IMMURON are of similar size ($7.0M and $6.9M). Brainstorm Cell Therapeutics Inc. has the higher net margin (0.00% vs −262.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Brainstorm Cell Therapeutics Inc. leads on 5 and IMMURON on 5.

Valuation

Metric BCLI IMRN Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.93 0.66
EV/Sales n/m (3.47) 9.02
Earnings yield (103.48%) (2.51%) (32.88%)
Free cash flow yield (40.91%) 0.00% (23.13%)

Profitability

Metric BCLI IMRN Biotechnology median
Gross margin 0.00% 71.28% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (262.71%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 119.20% 0.00% (51.96%)
Return on assets (627.43%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCLI IMRN Biotechnology median
Revenue growth (TTM) — (6.62%) 6.76%
EPS growth (last fiscal year) 51.95% 37.29% 29.88%
Revenue growth, 5-year CAGR — 116.96% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCLI IMRN Biotechnology median
Debt to equity (0.11) 0.00 0.00
Current ratio 0.03 7.26 4.97
Net debt to EBITDA (0.10) 1.81 1.01

Dividend

Metric BCLI IMRN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCLI IMRN Biotechnology median
Market cap 6.99m 6.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack